Edgewise Sells Muscle Drug Unit to Servier for $2.65B
Edgewise Therapeutics has agreed to sell its muscular dystrophy drug sevasemten and related business to Servier for an upfront cash payment of $1.55 billion. The deal allows Servier to expand into neurology while Edgewise focuses on developing its heart drug candidate EDG-7500.
EDGEWISE THERAPEUTICS INC will sell its muscular dystrophy business to Servier for up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in milestone payments. The experimental drug sevasemten targets Becker and Duchenne muscular dystrophy. The sale shifts focus to heart drug EDG-7500 and strengthens the balance sheet.
### Servier's Expansion into Neurology Edgewise shares rose 14.3% to a record $40.8 on Monday afternoon following the announcement. The transaction marks a pivot for Servier, a group based in France, as it expands beyond cancer and cardiovascular treatments. Servier CEO David Lee said the United States serves as the primary growth engine for this rare disease pivot.